RE: Myriad Genetics Precise MRDβ’............14 Apr 2026 14:46
This partnership aims to develop less-invasive, blood-based cancer tests by comparing Parsortix-harvested cells with Myriad's established tissue assays, potentially enabling large-scale, repeated testing.
Key Aspects of the Collaboration
Technology Focus: The Parsortix system captures intact cancer cells from blood for downstream analysis, as discussed in and shown in.
Objective: To develop improved, less invasive, and convenient liquid biopsy tests for cancer patients.
Methodology: R&D team will process samples, while Myriad will compare these results against matched patient tissue samples to validate the technology's effectiveness.
Potential Scale: If successful, this initiative could lead to widespread use of the Parsortix technology for testing hundreds of thousands of samples
Significance for Cancer Diagnostics
Improved Monitoring: Enables more frequent, less invasive monitoring of cancer through blood, replacing or supplementing traditional tissue biopsies.
High Sensitivity: Parsortix is known for its ability to effectively recover CTCs, which are crucial for molecular analysis, as shown in.
Commercial Potential: The collaboration utilizes consumable Parsortix cassettes, which, according to, offers a pathway to consistent revenue for clbx and potential strategic, exclusive, or proprietary testing advantages for Myriad.